Oxford Cancer Analytics (OXcan)

Focus
Liquid Biopsy
Location
Oxford
Investment date
Dec. 2024

Oxford Cancer Analytics (OXcan) is on a mission to drastically transform cancer early detection and management to impact millions of lives worldwide. OXcan’s multidisciplinary team is developing a new generation of liquid biopsy blood tests using cutting-edge proteomics and explainable machine learning approaches that can detect the deadliest cancers early, when they can still be cured.